The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GRFS | +10.1% | -45.48% | -11.42% | +66% |
| S&P | +14.5% | +93.32% | +14.09% | +410% |
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
The company gave first-quarter numbers.
Their dividends will be trickling into your account quarter after quarter.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.15B | 9.6% |
| Gross Profit | $810.99M | 21.4% |
| Gross Margin | 37.81% | 3.7% |
| Market Cap | $2.33B | 44.1% |
| Market Cap / Employee | $0.10M | 0.0% |
| Employees | 23.8K | 0.4% |
| Net Income | $156.97M | 488.8% |
| EBITDA | $506.49M | 29.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $655.82M | -71.0% |
| Accounts Receivable | $982.48M | 16.2% |
| Inventory | 3.9K | 1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $9.89B | 15.9% |
| Short Term Debt | $610.70M | -78.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 1.38% | 0.7% |
| Return On Invested Capital | 1.85% | -0.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $106.38M | -55.8% |
| Operating Free Cash Flow | $173.63M | -36.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 38.61 | 29.82 | 23.11 | 18.85 | -27.67% |
| Price to Book | 1.01 | 0.84 | 0.79 | 1.01 | 53.08% |
| Price to Sales | 0.79 | 0.65 | 0.61 | 0.76 | 30.31% |
| Price to Tangible Book Value | -0.49 | -0.41 | -0.40 | -0.39 | 20.30% |
| Price to Free Cash Flow TTM | 16.71 | 6.95 | 4.65 | 6.78 | -66.35% |
| Enterprise Value to EBITDA | 40.98 | 31.23 | 43.71 | 37.20 | -10.55% |
| Free Cash Flow Yield | 6.0% | 14.4% | 21.5% | 14.7% | 197.20% |
| Return on Equity | 2.5% | 2.7% | 3.3% | 5.4% | 103.91% |
| Total Debt | $11.00B | $9.53B | $10.85B | $10.50B | -7.91% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
